Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023985 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00023985: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT00023985 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023985, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have non-small cell lung cancer.
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
What the finished NCT00023985 record still lists
NCT00023985 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which conventional surgery is the first listed.
NCT00023985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00023985 about?
NCT00023985 is a clinical study titled "Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have non-small cell lung cancer.
What is the current status of trial NCT00023985?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-01. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00023985?
The interventions under investigation include: conventional surgery (PROCEDURE), autologous tumor cell vaccine (BIOLOGICAL), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00023985?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia